In response to: Gliflozins in the management of cardiovascular disease
Vol. 10 No. 2 (2023), Letter to the editor
Vol. 10 No. 2 (2023)

In response to: Gliflozins in the management of cardiovascular disease

Letter to the editor
https://doi.org/10.22265/acnef.10.2.640
Published 2023-02-24
Jorge Rico-Fontalvo
Comité de Nefro-diabetes, Asociación Colombiana de Nefrología e Hipertensión arterial, Bogotá, Colombia
https://orcid.org/0000-0002-2852-1241
Cristóbal Morales-Portillo
Endocrinología, Hospital Vithas Sevilla, Sevilla, España
https://orcid.org/0000-0003-0348-826X
José Bohórquez-Rivero
Grupo de Investigación GIBACUS, Universidad del Sinú, Cartagena de Indias, Colombia
https://orcid.org/0000-0002-9064-1068
PDF (Español (España))

Keywords

Glifozins
Anti-Inflammatory Agents
Kidney Diseases
Chronic Renal Insufficiency

How to Cite

1.
Rico-Fontalvo J, Morales-Portillo C, Bohórquez-Rivero J. In response to: Gliflozins in the management of cardiovascular disease. Rev. Colomb. Nefrol. [Internet]. 2023 Feb. 24 [cited 2023 Apr. 1];10(2). Available from: https://revistanefrologia.org/index.php/rcn/article/view/640
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

We have read with great interest the article by Braunwald (1) entitled Gliflozins in the management of cardiovascular disease, recently published in the New England Journal of Medicine, where the author provides an excellent review of SGLT2 inhibitors (iSGLT2) and their effects at the cardiovascular level; however, we consider it relevant to clarify certain points in this regard.

https://doi.org/10.22265/acnef.10.2.640
PDF (Español (España))

References

Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med 2022;386:2024-2034. https://doi.org/10.1056/NEJMra2115011

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. https://doi.org/10.1056/NEJMoa2024816

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. https://doi.org/10.1056/NEJMoa1811744

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dimensions


PlumX


Downloads

Download data is not yet available.

Most read articles by the same author(s)